Autobahn Therapeutics Completes Oversubscribed $100 Million Series C Financing to Advance Pipeline of Novel Therapeutics for Depression and Other CNS Disorders
Summary
Autobahns CNS pipeline, powered by its brain-targeting chemistry platform, has the potential to meaningfully impact the ways in which these debilitating disorders are treated, stated Dr. Cahill. With the proceeds from this raise, Autobahn will also advance ABX-101, a next-generation, brain-penetrant, oral sphingosine 1-phosphate (S1P) receptor modulator for the treatment of neuroimmunologic and neuroinflammatory disorders, into Phase 1 clinical testing. In preclinical studies, ABX-101 demonstrated exceptional CNS exposure and robust centrally mediated treatment effects in well-established animal models, as well as the ability to optimize peripheral immunomodulatory benefits. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. Thyroid hormone agonism has demonstrated activity on cellular energy metabolism pathways, which play an important role on the regulation of brain bioenergetics and may be uniquely suited to address symptoms of atypical depression, a highly prevalent and underserved sub-population of MDD.